Previous Close | 1,521.65 |
Open | 1,525.55 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's Range | 1,505.35 - 1,527.75 |
52 Week Range | 995.05 - 1,638.70 |
Volume | |
Avg. Volume | 90,180 |
Market Cap | 3.636T |
Beta (5Y Monthly) | 0.49 |
PE Ratio (TTM) | 38.00 |
EPS (TTM) | 39.87 |
Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
Forward Dividend & Yield | 13.50 (0.89%) |
Ex-Dividend Date | Jul 12, 2024 |
1y Target Est | N/A |
In this article, we will take a look at the 30 most valuable drug companies in 2024. If you want to skip our detailed analysis of the pharmaceutical drugs market, you can go directly to 5 Most Valuable Drug Companies in 2024. The Global Pharmaceutical Drugs Market According to a report by The Business Research […]
In this article, we will look into the top 20 most valuable Indian companies. If you want to skip our detailed analysis, you can go directly to the Top 5 Most Valuable Indian Companies. An Outlook of the Indian Economy According to Deloitte’s Indian Economic Outlook 2023, The Indian economy is poised to emerge as […]
Intratumoral Nidlegy™ followed by surgery significantly improved the Recurrence-Free Survival compared to surgery alone PIVOTAL (NCT02938299) is the first and so far only Phase III trial demonstrating statistically significant and clinically meaningful benefit of a neoadjuvant therapy in fully resectable locally advanced melanoma patients Nidlegy™ is the first immunocytokine product to show positive data in a Phase III randomized clinical trial The results will be presented at an upcoming intern